ES2053676T3 - Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. - Google Patents

Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.

Info

Publication number
ES2053676T3
ES2053676T3 ES88117833T ES88117833T ES2053676T3 ES 2053676 T3 ES2053676 T3 ES 2053676T3 ES 88117833 T ES88117833 T ES 88117833T ES 88117833 T ES88117833 T ES 88117833T ES 2053676 T3 ES2053676 T3 ES 2053676T3
Authority
ES
Spain
Prior art keywords
high ionic
recombinants
formulation
plasma proteins
ionic force
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88117833T
Other languages
English (en)
Spanish (es)
Inventor
Ted C K Lee
Michael E Hrinda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2053676(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of ES2053676T3 publication Critical patent/ES2053676T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
ES88117833T 1987-10-29 1988-10-26 Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada. Expired - Lifetime ES2053676T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29

Publications (1)

Publication Number Publication Date
ES2053676T3 true ES2053676T3 (es) 1994-08-01

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88117833T Expired - Lifetime ES2053676T3 (es) 1987-10-29 1988-10-26 Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.

Country Status (8)

Country Link
EP (1) EP0314095B1 (enExample)
JP (1) JP2544968B2 (enExample)
AT (1) ATE83155T1 (enExample)
AU (1) AU622133B2 (enExample)
CA (1) CA1329760C (enExample)
DE (1) DE3876600T2 (enExample)
ES (1) ES2053676T3 (enExample)
GR (1) GR3006506T3 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097120T3 (es) * 1989-07-24 1997-04-01 Bayer Ag Estabilizacion de proteinas altamente purificadas.
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4383546B2 (ja) 1997-04-28 2009-12-16 イーライ・リリー・アンド・カンパニー 活性化プロテインｃの改良プロセシング方法
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1561469A1 (en) * 1997-04-28 2005-08-10 Eli Lilly & Company Activated Protein C Formulations
ES2179414T3 (es) 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
PL198123B1 (pl) 1999-02-22 2008-05-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ES2653555T3 (es) 2002-06-21 2018-02-07 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
EP1539212A4 (en) * 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
KR20130026498A (ko) 2003-12-19 2013-03-13 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US8187799B2 (en) * 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
AU2009313325B2 (en) 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations
RU2013131911A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Водный раствор фактора viii
IN2014CN03555A (enExample) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
CN104519912A (zh) * 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
RU2018118836A (ru) * 2015-11-05 2019-12-05 Ново Нордиск А/С Препарат фактора свёртывания крови viii
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
WO2020185909A2 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
CA1329760C (en) 1994-05-24
DE3876600D1 (de) 1993-01-21
AU622133B2 (en) 1992-04-02
JPH01149733A (ja) 1989-06-12
EP0314095B1 (en) 1992-12-09
EP0314095A1 (en) 1989-05-03
GR3006506T3 (enExample) 1993-06-30
ATE83155T1 (de) 1992-12-15
DE3876600T2 (de) 1993-04-15
JP2544968B2 (ja) 1996-10-16
AU2452088A (en) 1989-05-04

Similar Documents

Publication Publication Date Title
ES2053676T3 (es) Formulacion de proteinas plasmaticas y recombinantes en medios de fuerza ionica elevada.
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
DK562888A (da) Aminomethyl-oxooxazolidinyl-cycloalkylbenzenderivater, fremstilling deraf, praeparater indeholdende disse og deres anvendelse som antibakterielle midler
PT758248E (pt) Formulacoes para o factor ix
AU573523B2 (en) Functional human urokinase proteins
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
FI91160B (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
GR1001040B (el) Ενζυμο σταθεροποιητικη συνθεση και συνθεσεις δομικου απορρυπαντικου που περιεχουν σταθεροποιητικο ενζυμο.
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
HUT47436A (en) Process for stabilizing pharmaceutically active proteines in pharmaceutical compositions
AU6368890A (en) Anticoagulant peptides
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
SE8502540D0 (sv) Stable dentifrice containing dextranase
EP0957936A4 (en) COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES
AU1174588A (en) Anticonvulsant agents
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
AU580890B2 (en) P-acylaminobenzamides
AU2323984A (en) Recombinant dna expression vectors useful in bacillus
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
DE69907727D1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 314095

Country of ref document: ES